Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status.
Shalata W, Maimon Rabinovich N, Agbarya A, Yakobson A, Dudnik Y, Abu Jama A, Cohen AY, Shalata S, Abu Hamed A, Ilan Ber T, Machluf O, Shoham Levin G, Meirovitz A.
Shalata W, et al. Among authors: abu jama a.
Cancers (Basel). 2024 May 10;16(10):1825. doi: 10.3390/cancers16101825.
Cancers (Basel). 2024.
PMID: 38791905
Free PMC article.